ERIC 2018 | Opinion on MRD in CLL: routine use or clinical trials?

Kanti Rai

Measurable residual disease (MRD) is moving into the clinical setting, attracting varying opinions on the method and setting of its use. Here. Kanti Rai, MD, of the Feinstein Institute of Medical Research, Manhasset, NY, discusses his thoughts on the impact and use of MRD in the chronic lymphocytic leukemia (CLL) space. This interview recorded at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.

Share this video